Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Dermatological Medicine
Volume 2015, Article ID 934247, 4 pages
http://dx.doi.org/10.1155/2015/934247
Case Report

Idiopathic Thrombocytopenic Purpura Misdiagnosed as Hereditary Angioedema

1Department of Otorhinolaryngology, Head and Neck Surgery, Køge Hospital, Lykkebaekvej 1, 4600 Køge, Denmark
2HAE Centre Denmark, Department of Dermatology and Allergy Centre, Odense University Hospital, Sdr. Boulevard 29, Entrance 142, 5000 Odense C, Denmark

Received 30 October 2015; Revised 5 December 2015; Accepted 15 December 2015

Academic Editor: Michihiro Hide

Copyright © 2015 Michelle Fog Andersen and Anette Bygum. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. I. Quincke, “Über akutes umschriebenes hautödem,” Monatschrift Praktische Dermatologie, vol. 1, no. 1, pp. 129–131, 1882. View at Google Scholar
  2. K. Bork, G. Meng, P. Staubach, and J. Hardt, “Hereditary angioedema: new findings concerning symptoms, affected organs, and course,” The American Journal of Medicine, vol. 119, no. 3, pp. 267–274, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Bygum, “Hereditary angio-oedema in Denmark: a nationwide survey,” British Journal of Dermatology, vol. 161, no. 5, pp. 1153–1158, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Agostoni, E. Aygören-Pürsün, K. E. Binkley et al., “Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond,” The Journal of Allergy and Clinical Immunology, vol. 114, no. 3, pp. S51–S131, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. A. E. Davis, “New treatments addressing the pathophysiology of hereditary angioedema,” Clinical and Molecular Allergy, vol. 6, no. 2, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. A. E. Davis, “The pathogenesis of hereditary angioedema,” Transfusion and Apheresis Science, vol. 29, no. 3, pp. 195–203, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. U. C. Nzeako, E. Frigas, and W. J. Tremaine, “Hereditary angioedema: a broad review for clinicians,” Archives of Internal Medicine, vol. 161, no. 20, pp. 2417–2429, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Zanichelli, F. Arcoleo, M. P. Barca et al., “A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy,” Orphanet Journal of Rare Diseases, vol. 10, article 11, 2015. View at Publisher · View at Google Scholar
  9. J. Björkqvist, S. de Maat, U. Lewandrowski et al., “Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III,” The Journal of Clinical Investigation, vol. 125, no. 8, pp. 3132–3146, 2015. View at Publisher · View at Google Scholar
  10. M. Magerl, G. Doumoulakis, I. Kalkounou et al., “Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema,” Clinical and Experimental Dermatology, vol. 39, no. 3, pp. 298–303, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Reshef, M. J. Prematta, and T. J. Craig, “Signs and symptoms preceding acute attacks of hereditary angioedema: results of three recent surveys,” Allergy and Asthma Proceedings, vol. 34, no. 3, pp. 261–266, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. B. L. Zuraw, “Hereditary angioedema,” The New England Journal of Medicine, vol. 359, no. 10, pp. 1027–1036, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Bowen, M. Cicardi, H. Farkas et al., “2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema,” Allergy, Asthma & Clinical Immunology, vol. 6, no. 1, article 24, 2010. View at Publisher · View at Google Scholar
  14. B. Visy, G. Füst, A. Bygum et al., “Helicobacter pylori infection as a triggering factor of attacks in patients with hereditary angioedema,” Helicobacter, vol. 12, no. 3, pp. 251–257, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Franchini and D. Veneri, “Helicobacter pylori-associated immune thrombocytopenia,” Platelets, vol. 17, no. 2, pp. 71–77, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Hagymási and Z. Tulassay, “Helicobacter pylori infection: new pathogenetic and clinical aspects,” World Journal of Gastroenterology, vol. 20, no. 21, pp. 6386–6399, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. E. I. B. Peerschke, B. Andemariam, W. Yin, and J. B. Bussel, “Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura,” British Journal of Haematology, vol. 148, no. 4, pp. 638–645, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. E. I. Peerschke, S. Panicker, and J. Bussel, “Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor,” British Journal of Haematology, 2015. View at Publisher · View at Google Scholar
  19. A. Agostoni and M. Cicardi, “Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients,” Medicine, vol. 71, no. 4, pp. 206–215, 1992. View at Google Scholar · View at Scopus
  20. T. Craig, E. A. Pürsün, K. Bork et al., “WAO guideline for the management of hereditary angioedema,” World Allergy Organization Journal, vol. 5, no. 12, pp. 182–199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Cicardi, K. Bork, T. Caballero et al., “Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group,” Allergy, vol. 67, no. 2, pp. 147–157, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. H. J. Longhurst, H. Farkas, T. Craig et al., “HAE international home therapy consensus document,” Allergy, Asthma & Clinical Immunology, vol. 6, no. 1, article 22, 2010. View at Publisher · View at Google Scholar
  23. K. Bork, A. Bygum, and J. Hardt, “Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients,” Annals of Allergy, Asthma & Immunology, vol. 100, no. 2, pp. 153–161, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. W. Hosea, M. L. Santaella, E. J. Brown, M. Berger, K. Katusha, and M. M. Frank, “Long-term therapy of hereditary angioedema with Danazol,” Annals of Internal Medicine, vol. 93, no. 6, pp. 809–812, 1980. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Maloisel, E. Andrès, J. Zimmer et al., “Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results,” The American Journal of Medicine, vol. 116, no. 9, pp. 590–594, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. S. Ahn, W. J. Harrington, S. R. Simon, R. Mylvaganam, L. M. Pall, and A. G. So, “Danazol for the treatment of idiopathic thrombocytopenic purpura,” The New England Journal of Medicine, vol. 308, no. 23, pp. 1396–1399, 1983. View at Publisher · View at Google Scholar · View at Scopus
  27. M. M. Gompels, R. J. Lock, M. Abinun et al., “C1 inhibitor deficiency: consensus document,” Clinical and Experimental Immunology, vol. 139, no. 3, pp. 379–394, 2005. View at Google Scholar
  28. U. C. Nzeako and H. J. Longhurst, “Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema,” European Journal of Gastroenterology & Hepatology, vol. 24, no. 4, pp. 353–361, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. G. R. Norman and K. W. Eva, “Diagnostic error and clinical reasoning,” Medical Education, vol. 44, no. 1, pp. 94–100, 2010. View at Publisher · View at Google Scholar · View at Scopus